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ABSTRACT
A missense mutation, FV-Ile359Thr (FV Liverpool), associated with thrombosis has recently been described. This mutation creates an additional potential N-linked glycosylation site (Asn-X-Ser/Thr) in factor V (FV) at Asn357 that could interfere with secretion and/or protein interactions. To investigate the molecular pathology of FV-Ile359Thr, the mutation was created by site-directed mutagenesis and expressed, together with other mutations that could help explain the phenotype (FV-Arg306Gln/Ile359Thr/Arg679Gln, FVIle359Thr/Arg506Gln/Arg679Gln and FV-Asn357Gln/Ile359Thr). The FV-Ile359Thr was secreted normally and had full procoagulant activity. Western-blot-analysis showed that FVIle359Thr migrated slower, while the FV-Asn357Gln/Ile359Thr was indistinguishable from FV-wild type (WT), indicating that FV-Ile359Thr was expressed with an additional carbohydrate chain. APC-mediated inactivation in a FVa degradation assay showed that the Ile359Thr mutation significantly reduced the cleavage at Arg306 both in the presence and absence of protein S, whereas the cleavage at Arg506 was unaffected. When tested in an FVIIIa degradation assay, the FV-Ile359Thr variant exhibited equally low APC-cofactor activity as FV Leiden (FV-Arg506Gln). In conclusion, the Ile359Thr mutation appears to affect anticoagulation by two mechanisms, impeding the APC-mediated down regulation of the FVa molecule, and additionally being a poor APC cofactor for the down regulation of FVIIIa. These findings explain the association of the FV-Ile359Thr mutation with thrombosis.
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INTRODUCTION
Factor V (FV) is a 330-kDa large glycoprotein circulating in plasma at a concentration of 7 ug/ml 1 . FV has a mosaic-like structure; its domain organization A1-A2-B-A3-C1-C2 is homologous to that of factor VIII (FVIII) 2, 3 . After activation through limited proteolysis by either thrombin or factor Xa (FXa), the B-domain dissociates from FVa 4, 5 . FVa, comprised of the noncovalently associated heavy and light chain, serves as an essential cofactor to FXa in the activation of prothrombin to thrombin. The procoagulant activity of FVa is down regulated by activated protein C (APC), which together with its cofactor protein S, inactivates
FVa through proteolytic cleavages at Arg306, Arg506 and Arg679 6 . In addition to its procoagulant activity, FV has anticoagulant properties, as it has been shown to function as a cofactor to APC, in synergy with protein S, in the down regulation of FVIIIa 7, 8 . Consequently . Less than a decade ago it was found that many patients with venous thrombosis were resistant to APC, and in 90% of the cases the APC resistance was caused by a missense mutation in FV replacing Arg506 with Gln 12, 13 . As a consequence this FV variant, designated FV Leiden, is resistant to APC cleavage at Arg506. This impairs not only the down regulation of the procoagulant activity of FVa, but also the anticoagulant cofactor activity of FV, as the Phospholipid vesicle preparation. The phospholipid stocks were dissolved in chloroform/methanol (9:1, v/v) and the concentrations were determined by phosphate analysis 23 . Mixtures of the lipids were prepared in chloroform/methanol (9:1, v/v) and kept at -20°C.
Aliquots were drawn from the stocks and dried in a glass tube under a mild flow of nitrogen.
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The phospholipids were suspended in 25 mM Hepes, 150 mM NaCl (pH 7.5), vigorously vortexed for 2 min and then sonicated for 10 min at room temperature at amplitude 3, using an XL 2020 sonicator (Misonix, New York, USA). Fresh phospholipid vesicles were prepared every day.
Site-directed mutagenesis. Mutations were introduced into the expression vector pMT2 containing the full-length cDNA of human FV using the QuikChange Site-directed mutagenesis kit (Stratagene, La Jolla, CA). For each mutant two complementary oligonucleotides were used containing the appropriate mutations. The Ile359Thr and the Asn357Gln/Ile359Thr variants were constructed using wild type (WT) FV cDNA as template.
The sense primer for the Ile359Thr variant was (Underlined nucleotides causing the mutations). To ascertain that no other mutation had occurred during the amplification, the 1.5 kb fragments containing the mutations were isolated after cleavage with restriction enzymes Bln I and Bsu 36I. These fragments were inserted into the WT template cleaved with the same enzymes. The sequences of the fragments were confirmed by DNA sequencing. The three FV variants FV-Arg506Gln, Arg306Gln/Arg679Gln and FV-Arg506Gln/Arg679Gln have been previously described 9,18 .
The FV-Arg306Gln/Ile359Thr/Arg679Gln variant was constructed using the FVArg306Gln/Arg679Gln construct as template. After PCR the DNA fragment encoding the Ile359Thr mutation was isolated by Bln I and Bsu 36I digestion. The 1.5 kb fragment was used to replace the corresponding fragment in the Arg306Gln/Arg679Gln construct. The replaced fragment encoding the Arg306Gln and the Ile359Thr mutations was subjected to DNA sequence analysis. In addition the Arg679Gln mutation was also confirmed by DNA The remaining FVa-cofactor activity was determined as previously described 18 . To calculate apparent second order rates for FVa cleavage, the inactivation curves obtained in the FVa inactivation assay were fitted to an equation as previously reported 26 with the following modification due to the fact that only one cleavage occurs in these FV variants. The use of this equation requires that the inactivation curves are independent of FVa concentration and that the rates are linear for varying APC concentration, thus control experiments were performed and the inactivation curves were found to fulfill these criteria.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From APC-resistance testing of plasma containing recombinant FV variants. APC sensitivity ratios were measured using Coatest APC-Resistance kit (Chromogenix), as described previously 18 . Recombinant FV variants were added to FV-depleted plasma (Biopool, CA, USA) to a final concentration of 1.2 nM. The FV deficient plasma was supplemented with 160 nM human protein S because we observed that some FV-deficient plasmas were low in protein S activity. The samples were then run according to the manufacturer's instructions.
The APC sensitivity ratios were also tested with low concentrations of protein S (20 nM).
Prior to the APC-resistance test described above, the FV-deficient plasma was 
APC-mediaed cleavage of the 506-507 bond of FVa-Ile359Thr
Inactivation of FVa-WT by APC is known to be a biphasic reaction, due to the rapid cleavage at Arg506, yielding a partially active intermediate, followed by the slower cleavage at Arg306 which results in complete loss of FXa cofactor activity 6, 26 . To investigate if the Ile359Thr mutation had a selective influence on the cleavage at Arg506, the FVaArg306Gln/Ile359Thr/Arg679Gln and the FVa-Arg306Gln/Arg679Gln variants were inactivated in parallel over time (Fig. 3A) . These two variants can only be cleaved at Arg506 
APC-mediated cleavage of the 306-307 bond of FVa-Ile359Thr
The influence of the FV-Ile359Thr mutation on the Arg306-cleavage was analyzed by comparing the inactivation of FV variants that could only be cleaved at the Arg306 site (FVIle359Thr/Arg506Gln/679Gln and FV-Arg506Gln/679Gln). The inactivation reactions were performed at 0.05 nM APC in the presence of protein S and at 1.3 nM APC in the absence of protein S. FVa-Ile359Thr/Arg506Gln/Arg679Gln was inactivated significantly slower than FVa-Arg506Gln/Arg679Gln both in the absence and in the presence of protein S (Fig. 4A and   4B ). Using these experimental data, apparent second order rate constants were calculated for the Arg306 cleavage. In the absence of protein S the rate constants were 1. The experiments investigating the rate of Arg306 cleavage in the presence of protein S were performed at physiological concentrations of protein S. To elucidate whether the mutant FVa variants responded differently than FVa-WT, the protein S concentrations were varied in the APC-mediated inactivation (Fig. 5) . The FVa variant carrying the Ile359Thr mutation (Ile359Thr/Arg506Gln/Arg679Gln) was found to require higher levels of protein S for efficient inactivation than FVa without the Ile359Thr mutation indicating that the attached carbohydrate could possibly interfere with the protein S function.
Restoring the APC-mediated FVa inactivation by elimination of the glycosylation site
A FV-Ile359Thr variant with the glycosylation site eliminated at 357, FVAsn357Gln/Ile359Thr, was generated to elucidate if the attenuated APC degradation was specific to the additional glycosylation, or if it was caused by the Ile359Thr substitution per se. Western blot analysis following APC cleavage showed the migration of the 306-506 fragment of FVa-Asn357Gln/Ile359Thr and FVa-WT to be indistinguishable (Fig 6A) . This observation further supports the interpretation that the elevated apparent molecular weight of the APC fragment 306-506 of the FV-Ile359Thr was as a result of additional glycosylation at Asn357. The FVa-Asn357Gln/Ile359Thr was also tested in the inactivation assay, to assess if the APC degradation of FVa was restored when glycosylation at Asn357 was prevented by the Asn357Gln substitution whilst in the context of the Ile359Thr mutation (Fig 6B) . The results indicated that FVa-Asn357Gln/Ile359Thr was inactivated as efficiently as FVa-WT.
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APC-resistance testing of the FV-Ile359Thr mutant
To investigate the effect of the Ile359Thr mutation in the APC resistance test, FV-Ile359Thr, FV-WT and FV-Arg506Gln were added to FV deficient plasma, which was then subjected to the APC-resistance test. In the test, the ratio between the clotting times in the presence and absence of APC was calculated. The ratio obtained in the presence of FV-WT was 2.1, whereas the ratio of FV-Arg506Gln was 1.3. The FV-Ile359Thr yielded a ratio of 1.9. This is in accordance with the finding that the plasma from the patients with the Ile359Thr mutation yielded an APC ratio intermediate of heterozygous FV Leiden plasma and normal plasma 19 .
As the inhibitory effect of the Ile359Thr mutation on the FVa inactivation was more prominent at low concentrations of protein S, the APC sensitivity ratio was also examined at lower concentrations of protein S. At 20 nM protein S, the APC ratios were 1.8, 1.7 and 1.2 for FV-WT, FV-Ile359Thr and FV-Arg506Gln, respectively, indicating that the concentration of protein S did not significantly affect the APC-resistance ratios.
APC-cofactor activity of FV-Ile359Thr
The APC-cofactor activity of FV-Ile359Thr was tested in a FVIIIa-degradation assay that specifically measures the APC-cofactor function of FV. In this assay, a preformed tenase complex, i.e.the FVIIIa:FIXa complex assembled on the surface of a phospholipid membrane, was incubated with APC, protein S and the different FV variants. After the APC-mediated degradation of FVIIIa, the residual ability of the tenase complex to generate FXa was For Arg306 . However, we were not able to detect any significant impairment on the cleavage at Arg506. The rate of the Arg306-cleavage was significantly reduced by the Ile359Thr mutation both in the presence and in the absence of protein S. The inhibitory effect of the Ile359Thr mutation on the Arg306 cleavage was more prominent at low concentrations of protein S.
Despite this objective evidence that the Ile359Thr mutation reduces the rate of inactivation of FVa by APC in a purified assay, when examined in the plasma APCR assay, the APC resistance ratio was only marginally reduced. The plasma APCR assay used in this study has been optimized to demonstrate resistance to APC by the FV-Arg506Gln substitution and may not have sufficient sensitivity to clearly demonstrate APCR due to FV-Ile359Thr.
Little is known about how APC and protein S bind to FV. Based on a peptide inhibition study it was suggested that protein S could interact with residues 493-506 28 . Moreover, residues 1865-1874 in the light chain of FVa have been suggested to be important for APC binding, as peptides encompassing this region were found to inhibit FVa inactivation 29 . However, these residues are buried inside the protein core in the three dimensional-model of FVa, suggesting this region may not have any physiological role 30 . Residue 357 is located rather distant from the cleavages at Arg306 and Arg506, which argues against this residue being directly 
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In summary, we have functionally characterized a novel mutation associated with thrombosis.
The FV-Ile359Thr is expressed with an additional carbohydrate chain at Asn357 that attenuates down regulation of FVa. In addition, the anticoagulant APC-cofactor function of the FV-Ile359Thr molecule was found to be impaired. As a consequence, FV-Ile359Thr appears to affect anticoagulation by two mechanisms; it is a poorer APC substrate impeding the regulation of the FVa molecule, and also the APC cofactor activity is reduced which results in defective FVIIIa degradation. These findings explain the association of the Ile359Thr mutation with thrombosis.
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Recombinant FV variants (0.8 nM) were activated with thrombin. APC (0.050 nM) was added to the reaction mixture containing protein S (0-100 nM) and 10/20/70 w/w/w PS/PE/PC phospholipids (25 uM) . The inactivation reactions were stopped after 10 min by dilution and activity was measured as described in legend to figure 3 . The values were normalized to the 
